Ivan Arnaud

hi. 🌃 | Postdoctoral Research Fellow @ UT MD Anderson | Cancer research • Internal Medicine • 📚 | Opinions are only my own.

[Ivan Arnaud @IvanArnaud]

Hey there #MedTwitter!

I’m Ivan Arnaud, postdoc fellow at @UTMDAnderson and IMG from @TecSaludMX 🇲🇽 applying to Internal Medicine #Match2027

I am passionate about #HemOnc research and difficult clinical cases. Into literary fiction and expository nonfiction📚

AAMC ID: 15731886

[Ivan Arnaud @IvanArnaud]

@UroDhino @UTMDAnderson @TecSaludMX Muchas gracias! ☺️

[Ivan Arnaud @IvanArnaud]

Hey there #MedTwitter!

I’m Ivan Arnaud, postdoc fellow at @UTMDAnderson and IMG from @TecSaludMX 🇲🇽 applying to Internal Medicine #Match2027

I am passionate about #HemOnc research and difficult clinical cases. Into literary fiction and expository nonfiction📚

AAMC ID: 15731886

[Ivan Arnaud @IvanArnaud]

@AcevedoJessicaE @UTMDAnderson @TecSaludMX 🥹 Thank you so much, friend!

[Ivan Arnaud @IvanArnaud]

@PaulyCarrera @UTMDAnderson @TecSaludMX Gracias!! ☺️

[Ivan Arnaud @IvanArnaud]

@gabypeof @UTMDAnderson @TecSaludMX Gracias ! ☺️

[Ivan Arnaud @IvanArnaud]

@gabypeof Tqmm

[Ivan Arnaud @IvanArnaud]

Thank you to @ProjectImg for providing such valuable resources that have helped me along this journey!

[Ivan Arnaud @IvanArnaud]

��😍😍

[NEJM @NEJM]

In a randomized phase 2 trial involving adults with AML, azacitidine–venetoclax led to longer event-free survival than induction chemotherapy, with a lower risk of severe infection and hemorrhage. Full PARADIGM trial results: https://t.co/iiDNsw6CUW

Editorial: Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML https://t.co/zsAPQjxEDb

[Ivan Arnaud @IvanArnaud]

@d_ramonfaur That is great to hear! Thank you!

[Ivan Arnaud @IvanArnaud]

So thankful for every person that has helped on this journey 🥰

[Ivan Arnaud @IvanArnaud]

Tonight’s gym session is brought to you by two shots of espresso, one red velvet mini cupcake and one Pulparindo. 🙂‍↕️

[Ivan Arnaud @IvanArnaud]

@sofiralonso Sofifas, c��mo es que sabes todo de todos los deportes??

[Ivan Arnaud @IvanArnaud]

Objective: Lose weight
Obstacle: My PI’s impecable taste for curating the snack drawer
🫪

[Ivan Arnaud @IvanArnaud]

Calm Saturday at the lab :) 🧫👨🏻‍🔬

[Ivan Arnaud @IvanArnaud]

Happy to have received the OET Gold Badge for my performance on the OET Medicine exam. Another step completed toward ECFMG certification and the Internal Medicine Match.
#Match2027
https://t.co/7mCpWnZxFc

[Ivan Arnaud @IvanArnaud]

Happy to share I've passed USMLE STEP 2 CK and achieved the score I was aiming for. 😄 Looking forward to the #Match2027 and the next challenges ahead!

[Ivan Arnaud @IvanArnaud]

@shatterswift Us 🥲

[Ivan Arnaud @IvanArnaud]

What a WEEK 🥴

[Paolo Tarantino @PTarantinoMD]

BREAKING: The most controversial article of the year, claiming that early morning immunotherapy works better than in the afternoon, is now retracted.

After reading the responses provided by the authors to the inconsistencies raised in the web, the @NatureMedicine editors no longer have confidence in the integrity of the results. The only prospective evidence that time-of-day matters for immunotherapy is now gone.

https://t.co/aXUY6aekhl

To me, this means (at least) two things.

First, it confirms that prudence on this topic was and remains critical. For as inexpensive it may be to give a drug earlier or later in the day, it carries a much more relevant cost: the one of scientific integrity. We owe our patients to make decisions based on solid data. We should not give up this practice too easily, particularly in the presence of several concerning red flags.

Second, this retraction should also prompt a broader reflection on the current state of peer review, in which unpaid reviewers struggle to keep up with a steady rise in submitted papers. Journals need to improve the process by implementing a formal, consistent, in-depth review of each paper by paid professionals. A practice that, in this case, may have avoided a retraction arriving after 22 citations and after inclusion of this study in at least one meta-analysis. And possibly, after some physicians had already changed their practice in IO administration.

For a thoughtful recap of this story, I recommend this well-written new piece in @ScienceMagazine by Laura Agudelo. I’m grateful to Laura for including my perspective in the article.

https://t.co/qHM5fMjwQ3